Anders Himmelmänn

6.4k total citations · 2 hit papers
106 papers, 2.9k citations indexed

About

Anders Himmelmänn is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Anders Himmelmänn has authored 106 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Cardiology and Cardiovascular Medicine, 35 papers in Surgery and 17 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Anders Himmelmänn's work include Antiplatelet Therapy and Cardiovascular Diseases (53 papers), Acute Myocardial Infarction Research (21 papers) and Lipoproteins and Cardiovascular Health (20 papers). Anders Himmelmänn is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (53 papers), Acute Myocardial Infarction Research (21 papers) and Lipoproteins and Cardiovascular Health (20 papers). Anders Himmelmänn collaborates with scholars based in Sweden, United States and United Kingdom. Anders Himmelmänn's co-authors include Stefan James, Lars Wallentin, Robert F. Storey, Philippe Gabríel Steg, Richard C. Becker, Thomas Hedner, Steen Husted, Hugo A. Katus, Hans Denison and Mikael Knutsson and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Anders Himmelmänn

105 papers receiving 2.8k citations

Hit Papers

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic... 2019 2026 2021 2023 2020 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA
    2020 304 citations S. Claiborne Johnston, Pierre Amarenco et al. profile →
  2. Ticagrelor in Patients with Stable Coronary Disease and Diabetes
    2019 204 citations Philippe Gabríel Steg, Robert A. Harrington et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anders Himmelmänn Sweden 30 1.9k 743 450 397 377 106 2.9k
Meinhard Haltmayer Austria 32 1.3k 0.7× 785 1.1× 384 0.9× 221 0.6× 138 0.4× 62 2.8k
Hirofumi Soejima Japan 35 2.0k 1.0× 948 1.3× 510 1.1× 631 1.6× 226 0.6× 126 3.9k
Wilko Spiering Netherlands 32 1.5k 0.8× 525 0.7× 303 0.7× 594 1.5× 76 0.2× 170 3.3k
Giulia Renda Italy 27 1.9k 1.0× 746 1.0× 600 1.3× 276 0.7× 350 0.9× 111 3.5k
Monica Verdoia Italy 27 1.7k 0.9× 1.0k 1.4× 291 0.6× 271 0.7× 419 1.1× 190 3.0k
Karly Hamulyák Netherlands 47 2.3k 1.2× 824 1.1× 288 0.6× 371 0.9× 2.4k 6.4× 143 6.6k
Damiano Baldassarre Italy 28 1.5k 0.8× 890 1.2× 405 0.9× 687 1.7× 84 0.2× 95 3.1k
Ellie Kelepouris United States 13 1.9k 1.0× 803 1.1× 363 0.8× 459 1.2× 57 0.2× 34 4.5k
Shih‐Hsien Sung Taiwan 28 2.1k 1.1× 784 1.1× 359 0.8× 383 1.0× 96 0.3× 155 3.1k
Peer Grande Denmark 34 4.3k 2.3× 2.4k 3.2× 560 1.2× 798 2.0× 334 0.9× 147 6.5k

Countries citing papers authored by Anders Himmelmänn

Since Specialization
Citations

This map shows the geographic impact of Anders Himmelmänn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Himmelmänn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Himmelmänn more than expected).

Fields of papers citing papers by Anders Himmelmänn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Himmelmänn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Himmelmänn. The network helps show where Anders Himmelmänn may publish in the future.

Co-authorship network of co-authors of Anders Himmelmänn

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Himmelmänn. A scholar is included among the top collaborators of Anders Himmelmänn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Himmelmänn. Anders Himmelmänn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johnston, S. Claiborne, Ritika Jain, Pierre Amarenco, et al.. (2023). Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial. BMJ Neurology Open. 5(2). e000478–e000478.
2.
Heeney, Matthew M., Miguel R. Abboud, Jessie Githanga, et al.. (2022). Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 140(13). 1470–1481. 11 indexed citations
3.
Wang, Yongjun, Yuesong Pan, Hao Li, et al.. (2022). Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology. 99(1). e46–e54. 7 indexed citations
4.
Johnston, S. Claiborne, Pierre Amarenco, Hans Denison, et al.. (2021). Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. Stroke. 52(11). 3482–3489. 11 indexed citations
5.
Ueland, Thor, Axel Åkerblom, Tatevik Ghukasyan Lakic, et al.. (2019). ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis. 293. 35–41. 4 indexed citations
6.
7.
8.
Ducrocq, Grégory, Phillip J. Schulte, Andrzej Budaj, et al.. (2015). Balancing the risk of ischaemic and bleeding events in ACS. European Heart Journal. 36. 860–861. 1 indexed citations
9.
Andell, Pontus, Stefan James, Christopher P. Cannon, et al.. (2015). TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN ANALYSIS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology. 65(10). A114–A114. 1 indexed citations
10.
Wallentin, Lars, Annika E. Michelsen, Pål Aukrust, et al.. (2015). ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE (ALCAM) AND OUTCOMES IN ACUTE CORONARY SYNDROMES: A PLATO BIOMARKER SUBSTUDY. Journal of the American College of Cardiology. 65(10). A231–A231. 1 indexed citations
11.
Ducrocq, Grégory, Phillip J. Schulte, Richard C. Becker, et al.. (2015). Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 11(8). 737–745. 42 indexed citations
12.
Åkerblom, Axel, Stefan James, H. A. Katus, et al.. (2014). Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure : insights from the platelet inhibition and patient outcomes (PLATO) trial. European Heart Journal. 35. 202–203. 1 indexed citations
13.
Hagström, Emil, Niclas Eriksson, Åsa Johansson, et al.. (2013). Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? : - A Report From the Plato Gwas Study. Circulation. 128(22). 2 indexed citations
14.
Kang, Hyun‐Jae, Robert M. Clare, Runlin Gao, et al.. (2013). Abstract 17001: Net Clinical Benefits of Ticagrelor Compared With Clopidogrel in Asian Acute Coronary Syndrome Patients: A Plato Sub-Study. Circulation. 128. 2 indexed citations
15.
Kang, Hyun‐Jae, Robert M. Clare, Runlin Gao, et al.. (2013). Net Clinical Benefits of Ticagrelor Compared With Clopidogrel in Asian Acute Coronary Syndrome Patients : A Plato Sub-Study. Circulation. 128(22). 2 indexed citations
16.
Brilakis, Emmanouil S., Claes Held, Bernhard Meier, et al.. (2013). Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial. American Heart Journal. 166(3). 474–480. 23 indexed citations
17.
Lindholm, Daniel, Christoph Varenhorst, Christopher P. Cannon, et al.. (2013). TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL. Journal of the American College of Cardiology. 61(10). E1–E1. 4 indexed citations
18.
Wennerström, Martin, Sverker Hansson, Thomas Hedner, Anders Himmelmänn, & Ulf Jodal. (2000). Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood. Journal of Hypertension. 18(4). 485–491. 85 indexed citations
19.
Himmelmänn, Anders, et al.. (1994). Predictors of Blood Pressure and Left Ventricular Mass in the Young: The Hypertension in Pregnancy Offspring Study. American Journal of Hypertension. 7(5). 381–389. 9 indexed citations
20.
Himmelmänn, Anders, Lennart Hansson, Anders Svensson, et al.. (1988). Predictors of Stroke in the Elderly. Acta Medica Scandinavica. 224(5). 439–443. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meinhard Haltmayer Breakdown of academic impact, for papers by Hirofumi Soejima Breakdown of academic impact, for papers by Wilko Spiering Breakdown of academic impact, for papers by Giulia Renda Breakdown of academic impact, for papers by Monica Verdoia Breakdown of academic impact, for papers by Karly Hamulyák Breakdown of academic impact, for papers by Damiano Baldassarre Breakdown of academic impact, for papers by Ellie Kelepouris Breakdown of academic impact, for papers by Shih‐Hsien Sung Breakdown of academic impact, for papers by Peer Grande
Rankless by CCL
2026